CST, 40134T, DPP4/CD26 (D6D8K) Rabbit Monoclonal Antibody (IHC Formulated)

Monoclonal Antibody for studying DPP4. Validated for Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, DPP4/CD26 (D6D8K) Rabbit Monoclonal Antibody (IHC Formulated) (CST #40134) is ready to ship. Product Usage Information Immunohistochemistry (Paraffin): 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Immunohistochemistry (Paraffin) Specificity / Sensitivity DPP4/CD26 (D6D8K) Rabbit Monoclonal Antibody (IHC Formulated) recognizes endogenous levels of total DPP4 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu491 of human DPP4 protein. Background DPP4 (CD26) is a type II transmembrane glycoprotein expressed ubiquitously in most tissues and different cell types (1,2). The protein has a short cytoplasmic domain, a transmembrane domain, a flexible stalk fragment, and an extracellular fragment (2). Both the catalytic peptide hydrolase domain and the beta-propeller ligand binding domain are located in the extracellular fragment (2). DPP4 is a multifunctional protein that exists in both a membrane-bound form as well as an extracellular soluble form. As a peptidase, it removes N-terminal dipeptides sequentially from proteins with a proline or alanine as the penultimate P1 amino acid (3,4). DPP4 has been shown to cleave a wide range of substrates, including GLP-1, BNP, substance P, etc. It is also involved in the regulation of related biological functions (5). In addition to its peptidase activity, DPP4 interacts with multiple important cell surface ligands, such as adenosine deaminase, fibronectin, and IGF2 receptor, to influence processes like T cell activation, cell migration, and proliferation (5). Several DPP4 inhibitors have been developed and their effects have been tested in the field of diabetes, cardiovascular disease, and tumor immunity (2,5,6). This product detects a SARS-CoV-2-related target for research into the mechanisms of the Novel Coronavirus, which has caused the COVID-19 pandemic. Alternate Names ADABP; ADCP-2; ADCP2; Adenosine deaminase complexing protein 2; CD26; Dipeptidyl peptidase 4; Dipeptidyl peptidase 4 membrane form; Dipeptidyl peptidase 4 soluble form; Dipeptidyl peptidase IV; Dipeptidyl peptidase IV membrane form; Dipeptidyl peptidase IV soluble form; dipeptidyl-peptidase 4; dipeptidylpeptidase 4; dipeptidylpeptidase IV (CD26, adenosine deaminase complexing protein 2); DPP IV; DPP4; DPPIV; Gly-Pro naphthylamidase; Post-proline dipeptidyl aminopeptidase IV; T-cell activation antigen CD26; TP103; Xaa-Pro-dipeptidylaminopeptidase Specification REACTIVITY: H SENSITIVITY: Endogenous Source/Isotype: Rabbit IgG